Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.

Asian Pacific journal of cancer prevention : APJCP - 1 Sept 2020

Yow Ka Shing, Liu Xin, Chai Chean Nee, Tung Moon Ley, Yan Benedict, Christopher Dheepa, Ong Kiat Hoe, Ooi Melissa G

Abstract excerpt

JAK2 (V617F) allelic burden is the main genetic driver behind and a potential differentiator between individual myeloproliferative neoplasm (MPN) subtypes. This study aimed to explore the relationship between JAK2 (V617F) allelic burden, MPN subtypes and their clinico-haematological manifestations in a Singapore-based cohort. Analysis was performed on a retrospectively collected dataset of 128 patients diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Philadelphia Chromosome

Share to Prognosis

Share to Singapore

Source

Open in PubMed Open full text

Identifiers

PMID: 32986384
DOI: 10.31557/APJCP.2020.21.9.2805
PMCID: PMC7779444

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.PMID 32986384Read ↗

High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Molecular pathogenesis of the myeloproliferative neoplasms.Semantic proximity Read ↗

[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].Semantic proximity Read ↗

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

Clonal Hematopoiesis and Mutations of Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients.Semantic proximity Read ↗

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

Update from the latest WHO classification of MPNs: a user's manual.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.